May 16, 2008
| Bio-IT World

Top Headlines

23andMe: Avey Proposes New Personal Genomics Paradigm
| Bio-IT World | 23andMe cofounder Linda Avey wowed the audience at the 2008 Bio-IT World Expo with her keynote presentation on the possibilities for personal genomics. more
Drug Side-Effects Prompt Tougher Code in U.K.
| Financial Times | Pharmaceutical companies must do more to encourage identification of side effects of their medicines, under a new industry code of practice published on Thursday. more
FDA Approves Ziopharm’s Orphan Drug
| Forbes | Ziopharm Oncology has received orphan drug approval from the FDA for Palifosfamide for the treatment of soft tissue sarcoma. more

MORE NEWS BELOW

Get Adobe Flash player


FDA Official Sees Push for Clinical Trial Rules
| FDA News | The FDA and the HHS Office for Human Research Protections are working on a final rule for registering institutional review boards, the first of the FDA’s efforts to issue regulations instead of guidances for clinical trials. more
International Team Sequences Platypus Genome
| IHT | Scientists announced the first decoding of the platypus genome on Wednesday, saying the findings provided "many clues to the function and evolution of all mammalian genomes.” more
Researchers Launch Online Protein Folding Game
| HHMI News | Howard Hughes Medical Institute researchers are bringing the arcane world of protein folding to the online gaming arena with the launch of “Foldit,” a free game in which players around the world compete to design proteins. more

White Papers & Special Reports

gq92112

This Bio•IT World Briefing On “Next-Generation Sequencing,”underwritten by GenomeQuest, Inc.,
presents a selection of feature stories, interviews,commentaries, conference reports, and editorials on the emergence, opportunities, and challenges posed by high-throughput sequencing. Covered in this collection: the launch of new
platforms from Applied Biosystems and Helicos; new applications of nextgen sequencing; the rise of personal genomics; and informatics solutions to vexing problem of managing the vast volumes of next-gen data.  Download now 



sgi_hybrid

SGI's Meeting Today’s Computational Needs for Science

The quest to better understand disease mechanisms and find new treatments is driven by new laboratory technologies and ever-more sophisticated modeling and simulation efforts. As such, life sciences R&D investigations increasingly are relying on more powerful computing resources. The challenge is how to accommodate the broad mix of applications.

Addressing this issue, this paper produced by the Bio-IT World Custom Publishing Group discusses a new SGI Hybrid Computing Environment approach. It optimally uses shared memory systems, multi-processor clusters, and FPGAs to accelerate computational workflows.



sgi_protm

SGI's Supercharging Proteomics Discovery

The deeper study of proteins and their interactions can reveal scientific information once considered nearly untouchable to scientists and researchers. Today, unprecedented advancements in computing power are enabling the creation of mounds of proteomic based data along with the accompanying bottlenecks data can create.

Rather than just “simplify the experiment” to fit the computational resources an alternative is now available with the SGI Proteomics Appliance. This complimentary white paper, produced by the Bio-IT World Custom Publishing Group, looks at ways to use the Proteomic Appliance to handle the most intensive proteomics computing tasks facing science today.





Expert Comment

Is Informed Consent as Ethical as It Could Be?

By Karl E. Peace

March 17, 2008 | The article New England IRB on Ethical Issues in Recruiting Patients, in the March 3, 2008, issue of eCliniqua served as a reminder to those involved with the execution of clinical trials of the importance of exercising due diligence to ensure that all aspects of clinical trial conduct are ethical.

I would like to bring to the attention of readers of eCliniqua some of my thoughts about making the informed consent process more ethical.  Many are aware, particularly in Phase III confirmatory proof of efficacy trials, that the determination of sample size carries with it an efficacy imperative.  That is, in order to confirm a question regarding efficacy of a compound, it is imperative that the sample size of the trial be large enough to provide a priori a high probability (large power) that the question will be answered. Read more.

Bio-IT World encourages readers to share their opinions on issues of interest to the life sciences community. To submit a commentary for consideration, contact Kevin Davies.

Life Science Webcasts & Podcasts

Waters

Automate Method SOPs for Greater Efficiency and Fewer Errors with Waters® NuGenesis® Intelligent Procedure Manager

waters podcastThe Waters® NuGenesis® SDMS Intelligent Procedure Manager is a workflow software package designed to guide the laboratory analyst through a routine, comprehensive method standard operating procedure (SOP) and integrate results with a chromatography data system. The Intelligent Procedure Manager addresses the predominately manual activities required to perform an analytical method or test, reducing cycle times up to 50-75% as compared to a traditional paper trail with fewer opportunities for human error.  From late-stage development to final product quality control and lot release, Intelligent Procedure Manager can be applied to any lab environment where rigorous adherence to approved test methods and SOPs must be followed, including compliance requirements for cGMP operations. Download Now


More Podcasts


Bio-IT Briefs

| Bio-IT World | FULL STORIES


Job Openings

Lilly Singapore Center for Drug Discovery (LSCDD) - Associate Director of Informatics
Lead and mentor a strong team for the Bioinformatics group at the Integrative Computational Sciences (ICS) department at LSCDD towards the development of novel algorithms, data analysis methods and software tools for drug discovery. Work closely with the Software Engineering group at ICS, and collaborate with the Discovery IT organization in Europe and USA. For additional information, or to apply visit: LSCDD 

 Lilly Singapore Center for Drug Discovery (LSCDD) - Senior Software Engineer
Join a strong team of software engineers in our Integrative Computational Sciences (ICS) at LSCDD. Collaborate with, and help develop integrated applications to process and visualize data from cutting-edge technologies used by scientists at Lilly Research Labs (LRL) and the Drug Discovery Research (DDR) teams. The Software Engineering team provides computational tools and tailored software solutions that enable the global effort of Tailored Therapeutics; ‘The Right Drug, at The Right Dose for The Right Patient at The Right Time'. For additional information, or to apply visit: LSCDD 

For reprints and/or copyright permission, please contact RMS, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext 100 or via email to bio-itworld@theygsgroup.com.